Brief: OpGen Subsidiary Curetis, Bioversys Sign Collaboration Agreement
25/10/2022 15:24
Oct 25 (Reuters) - OpGen Inc OPGN.O :
* OPGEN SUBSIDIARY CURETIS AND BIOVERSYS SIGN COLLABORATION
AGREEMENT FOR CLINICAL TRIAL SUPPORT
* OPGEN INC- UNYVERO PLATFORM FOR RAPID DIAGNOSTICS TO BE
USED IN
PHASE II CLINICAL TRIAL OF BV100
Source text for Eikon: ID:nGNX76mzYb
Further company coverage: OPGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CapForce
See all newsBrief: Opgen Says Financial Statements Contained Within Quarterly Report On Form 10-Q For Q1 2024 Should No Longer Be Relied Upon
Brief: Opgen Inc - Received Nasdaq Notice That Co Is Not In Compliance With Minimum Stockholders' Equity Requirement For Continued Listing
Brief: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
Brief: OpGen Announces 1-For-10 Reverse Stock Split
Brief: David E. Lazar Reports 19.9% Stake In Opgen Inc As Of March 25- SEC Filing